None
Conditions
Interventions
Oliceridine group:During induction of anesthesia, Oliceridine 0.06 mg/kg is administered intravenously.
Sufentanil group:During induction of anesthesia, Sufentanil 0.03 ug/kg is administered intravenously.
Sponsors
The Navy Specialized Medical Center of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–75 years, regardless of gender. 2. Body mass index (BMI) between 18.0–32 kg/m^2, with physical characteristics suitable for laryngeal mask airway management. 3. ASA physical status classification I–III, with ASA III patients deemed to have acceptable anesthetic risk after preoperative assessment. 4. Scheduled to undergo short-duration natural orifice transluminal urological surgery under general anesthesia without skin incision. 5. Written informed consent obtained from the participant or their legally authorized representative, with voluntary enrollment.
Exclusion criteria
Exclusion criteria: 1. Known allergy or history of severe adverse reactions to the study medications (oliceridine, cypofol, sufentanil). 2. Predicted difficult laryngeal mask airway insertion, such as severe limited mouth opening, restricted neck mobility, or Mallampati class IV. 3. Significant cardiopulmonary dysfunction (e.g., acute myocardial infarction, decompensated heart failure, or severe COPD) that may compromise airway safety during device placement. 4. Pregnant or lactating women. 5. Chronic opioid use (>7 days) preoperatively that may alter analgesic drug sensitivity. 6. Neurological disorders or impaired consciousness affecting accuracy of EEG monitoring. 7. Other clinically significant conditions deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laryngeal Mask Airway Insertion Conditions Score;Spontaneous Breathing Recovery Time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Anesthetic Dose;the trend of CSI;Hemodynamic Parameters;Emergence Adverse Events; | — |
Countries
China
Contacts
Public ContactMeimei Zhu
The Navy Specialized Medical Center of the People's Liberation Army of China
Outcome results
None listed